Michael Barbella, Managing Editor06.29.23
Enovis Corporation has closed the acquisition of Novastep, a subsidiary of Amplitude Surgical SA and global developer of clinically proven foot and ankle solutions.
Novastep strengthens Enovis’ position in the growing bunion segment with its best-in-class MIS bunion system, Pecaplasty, which accelerates U.S. growth. In addition, Novastep’s portfolio of CE marked forefoot and midfoot implants and robust OUS channel further the company’s international strategy.
“We are excited to welcome Novastep’s talented team to Enovis where we will work together to develop the next generation of foot and ankle solutions that improve patient outcomes,” Enovis CEO Matt Trerotola said.
Enovis Corporation develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The company’s range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. Its shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV.
Novastep strengthens Enovis’ position in the growing bunion segment with its best-in-class MIS bunion system, Pecaplasty, which accelerates U.S. growth. In addition, Novastep’s portfolio of CE marked forefoot and midfoot implants and robust OUS channel further the company’s international strategy.
“We are excited to welcome Novastep’s talented team to Enovis where we will work together to develop the next generation of foot and ankle solutions that improve patient outcomes,” Enovis CEO Matt Trerotola said.
Enovis Corporation develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The company’s range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. Its shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV.